European Partnership on Personalised Medicine
The European Partnership on Personalised Medicine (HORIZON-HLTH-2023-CARE-08-01) is a closed funding initiative under the Horizon Europe framework, aimed at revolutionising healthcare through tailored medical approaches. This partnership sought to foster collaborative research and accelerate the implementation of personalised medicine across Europe and beyond, focusing on prevention, diagnosis, and treatment. It brought together diverse stakeholders to drive innovation and improve health outcomes.
Who is Funded
The European Partnership on Personalised Medicine aimed to fund a broad range of entities, including governmental bodies and research institutions, across Europe and internationally, to advance personalised healthcare solutions. The primary goal was to enhance health outcomes by supporting innovative, patient-centred approaches.
What is Funded
This funding program supported a wide array of projects focused on personalised medicine, encompassing research, development, and implementation activities across various health-related sectors. It covered eligible costs related to these activities and targeted projects from fundamental research to pilot testing and market introduction.
Type and Scope of Funding
The European Partnership on Personalised Medicine was structured as a grant-based program under Horizon Europe. It featured a significant overall budget allocated for co-funded actions, with a specific funding rate for eligible costs and a clear maximum limit for financial support granted to third parties through the partnership.
Conditions and Requirements
Applicants and beneficiaries of the European Partnership on Personalised Medicine were subject to specific conditions covering application admissibility, consortium formation, and budget management. Adherence to these requirements was crucial for participation and effective implementation of the funded activities.
Application Procedure
The application process for the European Partnership on Personalised Medicine involved a single-stage submission, followed by a rigorous evaluation against predefined criteria. Applicants were informed of the outcomes through official communication channels.
Legal Basis
The European Partnership on Personalised Medicine operates under a robust legal framework, primarily established by key EU regulations that govern its mandate and operational guidelines. This ensures transparency and adherence to European funding policies.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
10,000,000 EUR
Allocated Budget:
100,000,000 EUR
Open Until:
Closed
Award Channel:
Framework Programme Call
Region:
European Union (EU Member States and Associated Countries), United States of America (legal entities established in the US are eligible to receive Union funding with consortium agreement). It is also open to third countries wanting to join.
Sectors:
Healthcare, Medical Technology, Pharmaceutical Industry, Research and Development, Information and Communication Technology, Social Enterprises, Other
Beneficiaries:
Health, prevention, counselling, hospice and palliative care
Application Type:
Consortium Required
Funding Stages:
Basic Research, Applied Research, Experimental Development, Prototyping, Pilot Testing, Capacity Building, Awareness Campaigns, Other
Funding Provider
Program Level:
European Union
Funding Body:
European Commission
Additional Partners:
International Consortium of Personalised Medicine (ICPerMed), European Research Area Network for Personalised Medicine (ERA-PerMed), EU4Health programme, Digital Europe Programme (DEP), European Social Fund Plus (ESF+), European Regional Development Fund (ERDF), InvestEU, Recovery and Resilience Facility (RRF), Technical Support Instrument (TSI), other European partnerships and missions, international organisations, non-European institutions and experts.
Website: